Observational, Multicenter Study on the Efficacy, Tolerability, and Safety of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis Older than 80 Years.

MLA

Mondoni, Michele, et al. “Observational, Multicenter Study on the Efficacy, Tolerability, and Safety of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis Older than 80 Years.” Respiration, vol. 102, no. 1, Jan. 2023, pp. 25–33. EBSCOhost, https://doi.org/10.1159/000527308.

APA

Mondoni, M., Alfano, F., Varone, F., Muscato, G., Conti, C., Saderi, L., Chiesa, A., Di Marco, F., Vancheri, C., Richeldi, L., Centanni, S., & Sotgiu, G. (2023). Observational, Multicenter Study on the Efficacy, Tolerability, and Safety of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis Older than 80 Years. Respiration, 102(1), 25–33. https://doi.org/10.1159/000527308

Chicago

Mondoni, Michele, Fausta Alfano, Francesco Varone, Giuseppe Muscato, Caterina Conti, Laura Saderi, Amerigo Chiesa, et al. 2023. “Observational, Multicenter Study on the Efficacy, Tolerability, and Safety of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis Older than 80 Years.” Respiration 102 (1): 25–33. doi:10.1159/000527308.